PURPOSE: This study is aimed at investigating the significance of gene promoter methylation status and protein expression of p16 INK4A and O6-methylguanine-DNA methyltransferase (MGMT) in the various uterine cervical lesions. MATERIALS AND METHODS: Methylation status by using methylation-specific polymerase chain reaction (MS-PCR) and protein expression by using immunohistochemistry for p16 INK4A and MGMT genes were performed in cervical squamous intraepithelial neoplasms (CIN), invasive squamous cell carcinomas (SCC), adenocarcinomas and non-neoplastic cervices. RESULTS: None of 20 non-neoplastic cervices showed p16 INK4A and MGMT gene hypermethylation, whereas at least one of these genes was hypermethylated with 50.0% (5/10) of CIN I, 65.0% (13/20) of CIN II-III, 70.2% (33/47) of SCC and 85.0% (17/20) of adenocarcinoma. p16 INK4A protein was totally negative in non-neoplastic cervices, but positive with 90.0% of CIN I, 100% of CIN II-III and adenocarcinoma, and 78.7% of SCC. MGMT protein was expressed in 10% of non-neoplastic cervices, but significantly increased in SCC (42.5%) and adenocarcinoma (70.0%). The protein expression of p16 INK4A and MGMT was not related to their gene promoter methylation status. CONCLUSIONS: The hypermethylation of p16 INK4A and MGMT genes in the uterine cervix may indicate the presence of malignant cells, and p16 INK4A immunostaining is useful in grading CIN and diagnosing invasive SCC and adenocarcinoma.
PURPOSE: This study is aimed at investigating the significance of gene promoter methylation status and protein expression of p16INK4A and O6-methylguanine-DNA methyltransferase (MGMT) in the various uterine cervical lesions. MATERIALS AND METHODS: Methylation status by using methylation-specific polymerase chain reaction (MS-PCR) and protein expression by using immunohistochemistry for p16INK4A and MGMT genes were performed in cervical squamous intraepithelial neoplasms (CIN), invasive squamous cell carcinomas (SCC), adenocarcinomas and non-neoplastic cervices. RESULTS: None of 20 non-neoplastic cervices showed p16INK4A and MGMT gene hypermethylation, whereas at least one of these genes was hypermethylated with 50.0% (5/10) of CIN I, 65.0% (13/20) of CIN II-III, 70.2% (33/47) of SCC and 85.0% (17/20) of adenocarcinoma. p16INK4A protein was totally negative in non-neoplastic cervices, but positive with 90.0% of CIN I, 100% of CIN II-III and adenocarcinoma, and 78.7% of SCC. MGMT protein was expressed in 10% of non-neoplastic cervices, but significantly increased in SCC (42.5%) and adenocarcinoma (70.0%). The protein expression of p16INK4A and MGMT was not related to their gene promoter methylation status. CONCLUSIONS: The hypermethylation of p16INK4A and MGMT genes in the uterine cervix may indicate the presence of malignant cells, and p16INK4A immunostaining is useful in grading CIN and diagnosing invasive SCC and adenocarcinoma.
Authors: Kwong Wai Choy; Chi Pui Pang; Ka Fai To; Christopher B O Yu; Joan S K Ng; Dennis S C Lam Journal: Invest Ophthalmol Vis Sci Date: 2002-05 Impact factor: 4.799
Authors: S L Rosas; W Koch; M G da Costa Carvalho; L Wu; J Califano; W Westra; J Jen; D Sidransky Journal: Cancer Res Date: 2001-02-01 Impact factor: 12.701
Authors: Y F Wong; T K Chung; T H Cheung; T Nobori; S F Yim; K W Lai; M Phil; A L Yu; M B Diccianni; T Z Li; A M Chang Journal: Gynecol Oncol Date: 1997-05 Impact factor: 5.482
Authors: S Ma; S Egyházi; T Ueno; C Lindholm; E L Kreklau; U Stierner; U Ringborg; J Hansson Journal: Br J Cancer Date: 2003-10-20 Impact factor: 7.640
Authors: I Tsoumpou; M Arbyn; M Kyrgiou; N Wentzensen; G Koliopoulos; P Martin-Hirsch; V Malamou-Mitsi; E Paraskevaidis Journal: Cancer Treat Rev Date: 2009-03-03 Impact factor: 12.111
Authors: Celine Pourreyron; Louise Reilly; Charlotte Proby; Andrey Panteleyev; Colin Fleming; Kathleen McLean; Andrew P South; John Foerster Journal: PLoS One Date: 2012-02-22 Impact factor: 3.240